Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 114

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 114
---
 that                                                                       
 we provide to the public, any changes in this guidance or our failure to meet this guidance; |

| ● | changes in the market valuations 
 of similar companies;            |

<div align='center'>58</div>

| ● | overall performance of 
 the equity markets;    |

| ● | sales of our Common Stock                 
 by us or our stockholders, in the future; |

| ● | trading volume of our Common 
 Stock;                       |

| ● | investor perceptions of                                                                                
 the investment opportunity associated with our Common Stock relative to other investment alternatives; |

| ● | actions by institutional  
 or activist stockholders; |

| ● | change in accounting standards,                      
 policies, guidelines, interpretations or principles; |

| ● | ineffectiveness of our 
 internal controls;     |

| ● | disputes or other developments                                                                                                          
 relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; |

| ● | significant lawsuits, including   
 patent or stockholder litigation; |

| ● | changes in the structure        
 of healthcare payments systems; |

| ● | issuance of additional                                                                                                
 shares of our Common Stock to comply with the full ratchet antidilution rights contained in our outstanding Warrants; |

| ● | failure to raise additional           
 funds on acceptable terms, or at all; |

| ● | changes in business or                                                                                                            
 regulatory conditions, including new laws or regulations or new interpretations of existing laws or regulations applicable to our 
 business;                                                                                                                         |

| ● | general political, economic,                                                       
 industry and market conditions, including rising interest rates and inflation; and |

| ● | other events or factors,              
 many of which are beyond our control. |

In addition, the stock market
in general, and the markets for special purpose acquisition company (“SPAC”) post-business combination businesses and healthcare
companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to
the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our Common
Stock, regardless of our actual operating performance. In addition, price volatility may be greater if the public float and trading volume
of our Common Stock is low. If the market price of our Common Stock falls, you may not realize any return on your investment and may
lose some or all of your investment. In the past, securities class action litigation has often been instituted against companies following
periods of volatility in the market price of a company’s securities